Influenza B: Prospects for the Development of Cross-Protective Vaccines

Liudmila M Tsybalova; Liudmila A Stepanova; Edward S Ramsay; Andrey V Vasin

doi:10.3390/v14061323

Influenza B: Prospects for the Development of Cross-Protective Vaccines

Viruses. 2022 Jun 17;14(6):1323. doi: 10.3390/v14061323.

Authors

Liudmila M Tsybalova¹, Liudmila A Stepanova¹, Edward S Ramsay¹, Andrey V Vasin^{1

2}

Affiliations

¹ Smorodintsev Research Institute of Influenza, Prof. Popova Str., 15/17, 197376 St. Petersburg, Russia.
² Research Institute of Influenza named after A.A. Smorodintsev, Peter the Great St. Petersburg Polytechnic University, Polytechnicheskaya, 29, 195251 St. Petersburg, Russia.

Abstract

In this review, we analyze the epidemiological and ecological features of influenza B, one of the most common and severe respiratory infections. The review presents various strategies for cross-protective influenza B vaccine development, including recombinant viruses, virus-like particles, and recombinant proteins. We provide an overview of viral proteins as cross-protective vaccine targets, along with other updated broadly protective vaccine strategies. The importance of developing such vaccines lies not only in influenza B prevention, but also in the very attractive prospect of eradicating the influenza B virus in the human population.

Keywords: cross-protection vaccines; influenza B; monoclonal antibodies; phylogenetic lineages; viral proteins; virus.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Viral
Cross Protection
Hemagglutinin Glycoproteins, Influenza Virus
Humans
Influenza Vaccines*
Influenza, Human* / epidemiology
Influenza, Human* / prevention & control
Orthomyxoviridae Infections*

Substances

Antibodies, Viral
Hemagglutinin Glycoproteins, Influenza Virus
Influenza Vaccines

Grants and funding

This research was funded by the strategic academic leadership program ‘Priority 2030′ of the Russian Federation (Agreement 75-15-2021-1333; 30.09.2021).